Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy of Remodulin in Adults With Congenital Heart Disease (ACHD) and Pulmonary Hypertension

Next Previous
Trial Profile

Efficacy of Remodulin in Adults With Congenital Heart Disease (ACHD) and Pulmonary Hypertension

Status: Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Treprostinil (Primary)
  • Indications Congenital heart defects; Pulmonary hypertension
  • Focus Therapeutic Use

Most Recent Events

  • 19 Sep 2017 Status changed from discontinued to withdrawn prior to enrolment.
  • 29 Jan 2016 Status changed from recruiting to discontinued, according to ClinicalTrials.gov record.
  • 03 Dec 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Apr 2016 to 1 Nov 2016.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top